Recently, the 2020 Maoshan Summit on Biotechnology & New Pharmaceutical Industry Development was jointly held by Changzhou Municipal People’s Government, Nanjing University of Technology (NanjingTech) and China Pharmaceutical University (CPU) in Jintan district, Changzhou. On of the speakers at the event was Prof. Xing Weihong, academician of Chinese Academy of Sciences (CAS) and vice president of NanjingTech, who delivered a keynote speech.
Following the Healthy China 2030 (HC 2030) program, Jintan grasped the opportunity to develop the biopharmaceutical industry. Focusing on biotechnology and new drugs as key part of the district’s layout of three new and one special industries, Jintan now has 42 biopharma-related enterprises above designated size. Currently, the 18.1-square kilometer-large Jintan Biopharmaceutical Industrial Park is under construction, preparing the district as a future cluster for high-end and top-class biomedical companies and projects. In addition, Jintan will actively participate in the integrated development of Yangtze River Delta, encourage local enterprises to take part in the key biomedicine-related industries of Jiangsu province and Shanghai municipality, and introduce or foster three - five API (active pharmaceutical ingredients) producers and five - ten corporate headquarters within three years. It is expected that such enterprises will altogether generate five billion yuan in industrial output value.
The same day, six programs were signed to settle within the industrial park, including the Jinling Pharmaceutical’s active ingredients and preparations of traditional Chinese medicine (TCM) and Western medicine, Jiangsu Xidian’microcrystalline cellulose as pharmaceutical excipients, and Jiangsu Alpha Pharmaceutical’s CDMO for APIs.
扫一扫在手机打开当前页  |
